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Abstract
Background: Adolescents in South Africa are at high risk of acquiring HIV. The HIV vaccination of adolescents could
reduce HIV incidence and mortality. The potential impact and cost-effectiveness of a national school-based HIV
vaccination program among adolescents was determined.
Method: The national HIV disease and cost burden was compared with (intervention) and without HIV vaccination
(comparator) given to school-going adolescents using a semi-Markov model. Life table analysis was conducted to
determine the impact of the intervention on life expectancy. Model inputs included measures of disease and cost
burden and hypothetical assumptions of vaccine characteristics. The base-case HIV vaccine modelled cost at US$ 12
per dose; vaccine efficacy of 50 %; duration of protection of 10 years achieved at a coverage rate of 60 % and
required annual boosters. Incremental cost-effectiveness ratios (ICER) were calculated using life years gained (LYG)
serving as the outcome measure. Sensitivity analyses were conducted on the vaccine characteristics to assess
parameter uncertainty.
Results: The HIV vaccination model yielded an ICER of US$ 5 per LYG (95 % CI ZAR 2.77–11.61) compared with the
comparator, which is considerably less than the national willingness-to-pay threshold of cost-effectiveness. This
translated to an 11 % increase in per capita costs from US$ 80 to US$ 89. National implementation of this intervention
could potentially result in an estimated cumulative gain of 23.6 million years of life (95 % CI 8.48–34.3 million years)
among adolescents age 10–19 years that were vaccinated. The 10 year absolute risk reduction projected by vaccine
implementation was 0.42 % for HIV incidence and 0.41 % for HIV mortality, with an increase in life expectancy noted
across all age groups. The ICER was sensitive to the vaccine efficacy, coverage and vaccine pricing in the sensitivity
analysis.
Conclusions: A national HIV vaccination program would be cost-effective and would avert new HIV infections and
decrease the mortality and morbidity associated with HIV disease. Decision makers would have to discern how these
findings, derived from local data and reflective of the South African epidemic, can be integrated into the national long
term health planning should a HIV vaccine become available.
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Background
South Africa has the largest human immunodeficiency
virus (HIV) epidemic in the world [1]. In 2012, 6.4 million
South Africans were living with HIV; 203,000 individuals
had lost their lives to it and another 395,000 South
Africans had acquired the infection [2, 3]. South Africa’s
life expectancy was understandably adversely affected by
the considerable burden of HIV disease [4]. However, life
expectancy had since increased from 53 years in 2006 to
61 years in 2012, and ensuring its continued improvement
remains a priority of the national department of health
[5]. The gains made in improving life expectancy are in no
small part attributable to ‘the largest antiretroviral (ART)
rollout in the world’ that South Africa has managed to
achieve [6]. To sustain this achievement is no mean feat.
The growing number of patients previously initiated on
ART need to be retained in care. While the public sector
retention rate approximates 75 % after one year on
treatment, South Africa needs to continuously enroll in
excess of 500 000 new patients onto ART annually to
maintain an ART enrolment ratio exceeding 1.3 [4].
This brings into question the long term sustainability of
the ART program considering the massive financial and
human resource implications the expansion of ART
program entails [7].
Data suggests that close to 25 % of all new HIV infec-
tions occurred among young women aged 15–24 years,
emphasizing this group as a major driver of the epidemic
[2]. The HIV prevalence in this age group is important
as it serves as a proxy for HIV incidence. HIV preva-
lence declined by 18 % in this age group from 2008 to
2012, from 8.7 % to 7.1 %, however there remains a need
for intensified prevention efforts [8]. Despite massive ac-
complishments made in establishing the ART program,
the women aged 15 – 24 years persist as the group with
the poorest access to this life-saving treatment. The bar-
riers that young people face in accessing public health
services has been well documented [9]. Issues concern-
ing lack of confidentiality and privacy, unfriendly and
judgmental attitudes of health care staff and inaccessible
clinic hours persist [10, 11]. It was against this backdrop
that the re-engineering of primary health care in South
Africa targeted the development of a school-based
sexual and reproductive health service as a priority [12].
The current HIV prevention program has enjoyed lim-
ited success in tackling the high rate of new infections in
South Africa, highlighting the need for an alternative
intervention. Vaccines are regarded at the most cost-
effective prevention intervention in the world [13]. Rerks-
Ngam et al tested the first HIV vaccine regimen (RV144/
Thai Trial) to show moderate vaccine efficacy in humans
in Thailand (2009) [14]. The study evaluated a prime-
boost strategy, priming with a recombinant canarypox
vector (ALVAC-HIV[vCP1521]) administered at baseline,
then at week 4, 12 and 24 with recombinant glycoprotein
120 subunit vaccine (AIDSVAX B/E) boosts given with
the ALVAC at weeks 12 and 24.
The prime-boost HIV vaccine regimen used resulted in
modest efficacy of 31 % over 3.5 years [14]. While the ef-
fects were not durable, they were indeed promising. After
undergoing modifications to optimize the HIV vaccine
regimen by making it Clade C specific and changing the
protein and adjuvant, a potential vaccine regimen was en-
tered into Phase I/IIb clinical trials at six major South
African centers to assess safety and immunogenicity (HIV
Vaccine Trial Network (HVTN) 100 study) [15]. Addition-
ally, a pivotal phase IIb/III HIV vaccine efficacy trial is
planned to take place in South Africa designated HVTN
702, which will evaluate the same regimen [as HVTN
100], should HVTN 100 prove to be immunogenic.
The aim of this analysis was to guide decision makers in
assessing the value of national implementation of a poten-
tial HIV vaccine among school-based adolescents in South
Africa. The work determined the impact of vaccination on
HIV disease burden and associated health costs, and eval-
uated the cost-effectiveness and potential changes in life
expectancy based on the premise that school-based care
would address the issues of equity and accessibility in
health care that adolescent South Africa faces.
Methods
The study methodology was compliant with the reporting
guidelines of the Consolidated Health Economic Evalu-
ation Reporting Standards (CHEERS) statement [16].
Study overview
Ten year old adolescents attending South African schools
in 2012 were considered for vaccination. This intervention
program was introduced as part of the national health ini-
tiative to introduce school-based sexual and reproductive
health services [12], and targeted learners prior to the on-
set of sexual activity. The cohort was modelled through a
lifetime horizon of 70 years inclusive, which exceeded the
current estimated life expectancy of 60.6 years in South
Africa [3]. The rationale for this was that life expectancy is
rapidly changing in the South African environment and
this cohort was considered to probably have a greater life
expectancy. The assumption made was that the HIV vac-
cine would be incorporated into the South African
Expanded Program of Immunization and would be ad-
ministered at school level. The health service provider
(provider) perspective was adopted as the information
generated was intended to inform national health decision
making. The hypothetical HIV vaccine was modelled as a
prevention strategy that reduced the HIV disease burden
and associated mortality. The vaccine strategies were con-
sidered against the system of HIV counselling and testing
(HCT) and the national rollout of ART that constituted
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the standard of care (comparator model) in South Africa
[17, 18]. The intervention model combined the current
standard of care with the HIV vaccination strategy as
both programs would be delivered simultaneously. A
discount rate of 3 % was applied to the economic costs
and health outcomes, as recommended by the World
Health Organization CHOosing Interventions that are
Cost-Effective (WHO-CHOICE) guidelines [19]. The
epidemiology of South African epidemic is described in
Table 1.
Outcome measures
Life years gained (LYG) was measured in terms of its
impact on mortality. The LYG concept represents a modi-
fied mortality measure which considers remaining life ex-
pectancy. More weight is accrued to the life of a young
child than an elderly person, because saving the life of a
young child will accrue more life years than saving the life
of an elderly person. The life years are calculated as the
“remaining life expectancy at the point of each averted
death” [20]. Life tables are generally setting specific or stan-
dardized for a geographic area. Using the information gen-
erated in these life tables, we are able to derive life
expectancies for a specific population.
The HIV vaccine described for implementation was
hypothetical as it is currently undergoing Phase I/II clinical
trials. The HIV vaccine characteristics were determined by
the target product profile formulated by the Pox-Protein
Private Public partnership (P5), developed to build on the
success of the RV144/Thai trial and evaluate potential HIV
vaccine candidates to determine their public health impact
[21]. The regimen included in this economic evaluation
mirrored the ongoing HVN 100 study which adapted the
ALVAC prime ALVAC/gp120/adjuvant boost of the
RV144/Thai trial but added an additional ALVAC/
gp120/adjuvant boost at month 12. This boost at
month 12 was added to circumvent the waning of the
immune response documented in the RV144/Thai trial
a year after initial vaccine administration.
The estimated vaccination coverage was 60 % (range: 40–
70 %). This represents a slight underestimation of the 68 %
reported for coverage of the 3rd dose of diphtheria, tetanus
and pertussis toxoid (DTP3) which has been validated as a
proxy for national immunization performance [22]. The
base-case HIV vaccine modelled cost US$ 12 per dose
(range: US$ 2–24), had a vaccine efficacy of 50 % (range:
30–70 %) and the duration of protection of 10 years
(achieved through the administration of annual boosters).
The declining immunity reported in the RV144/Thai trial
(particularly in the year following administration) reaffirmed
the need for booster injections. Annual boosters may be far
from pragmatic but merely represented an overestimation of
costs in this evaluation. The vaccine price of US$ 12 was
roughly based on the human papillomavirus (HPV) vaccine
available on government tender at US$ 17. Markedly re-
duced vaccines prices deemed plausible given the strides
made in negotiating lower priced ART medications and
HPV vaccines in the public sector [23, 24]. Pooled utilities
relating to HIV/AIDS (acquired immunodeficiency syn-
dromes) were derived from a meta-analysis and were used
for the cost-effectiveness analyses of HIV related interven-
tions [25].
Study inputs
Input parameters are shown in Table 2. Estimated vaccin-
ation coverage of 60 % of adolescents approximated 6 mil-
lion individuals receiving the initial course. Delivery of
health services was conducted at the schools. HIV related
costs were estimated identified from the 2013 national
HIV treatment guideline [18]. Patients would be consulted
by primary health care (PHC) nurses and more compli-
cated cases would be referred. Pharmaceutical costs in-
cluded ART, treatment of sexually transmitted infections
(STI) and condoms. In addition to the costs accumulated
in the comparator group, the intervention included the
vaccine and its delivery. Laboratory tests conducted by the
National Health Services Laboratory, costing of medica-
tion, consumables and additional pharmaceuticals and
Table 1 South African population by age groups exploring ARV treatment access. The HIV epidemiology of South Africa is described.
The treatment shortfall represents those eligible for ART but unable to access it
Age groups Population Susceptible Prevalencea On ARV treatmenta Treatment shortfallb
10–19 10 264 690 9 982 612 282 078 78 176 163 605
20–29 11 010 305 9 386 287 1 624 018 411 831 941 930
30–39 9 008 794 6 521 402 2 487 392 775 604 1 442 687
40–49 4 479 445 3 329 718 1 149 727 358 501 666 842
50–59 3 367 397 2 883 570 483 827 204 740 280 620
60+ 3 665 571 3 534 983 130 588 55 260 75 741
Totals 41 796 202 35 638 572 6 157 630 1 884 112 3 571 425
aShisana O et al. South African National HIV Prevalence, Incidence and Behaviour Survey, 2012. Cape Town, HSRC Press. 2014
bUN Joint Program on HIV/AIDS (UNAIDS). The Gap Report. 2014
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valuations of medical personnel cost based on the Uni-
form Patient Fee Schedule (UPFS) were sourced from the
National Department of Health. All costs were adjusted to
the common year 2012. Costs were converted from South
Africa rand (ZAR) to United States dollar (US$) using
the average exchange rate for 2012, thus allowing for
international comparison (US$ 1 = ZAR 8.21) [26]. HIV
related disease transition probabilities were obtained
from the South African literature and are shown in
Table 3.
Model based economic evaluation
Semi-Markov model development
Data capture and analysis was conducted in Microsoft
Excel® (Version 2010) (Microsoft Corp., Redmond, WA).
Ersatz version 1.2 (www.epigear.com), a boot-strap add-
Table 2 Parameter costs and economic considerations. The estimates were obtained from relevant South African literature for the
year 2012
HIV vaccine characteristics Value (Range) Reference
Coverage 60 % (40–70) Assumption
Price (US$) 12 (2–24) [47]
HIV vaccine efficacy 50 % (30–70) Assumption
Economics Value (Range) Reference
Cost discount rate 3.0 % (0–6 %) [19]
Outcome discount rate 3.0 % (0–6 %) [19]
International comparison (ZAR: 1US$) ZAR 8.21 - [26]
HIV disease related costs Distribution Value Reference
HIV prevention programme
HIV vaccine - 12 [21]
Vaccine delivery per dose Gamma 17 [48–52]
Existing prevention programme (incl. HR) Gamma 65 [49–53]
Voluntary counselling and testing (VCT) (per test) Gamma 23 [49, 50]
Cost of HIV rapid testing Gamma 2 [49, 50]
Current HIV programme (annual costs)
Asymptomatic treatment (not on ART) Gamma 131 [18, 53]
Symptomatic treatment (not on ART) Gamma 137 [18, 53]
AIDS treatment (not on ART) Gamma 182 [18, 53]
Patient on ART (average) Gamma 424 [18, 23]
ART cost (annual)
First-line regimen Gamma 10 [23]
Second-line regimen Gamma 27 [23]
Third-line regimen Gamma 173 [23]
Laboratory costs (annual)
First-line regimen (first year) Gamma 17 [18, 53]
First-line regimen (subsequent years) Gamma 46 [18, 53]
Second-line regimen Gamma 46 [18, 53]
Third-line regimen Gamma 92 [18, 53]
Not on ART Gamma 65 [53]
Table 3 Disease transition probabilities showing annual
progression risk. The possibility of transition from one HIV
health state to the next is described. The estimates were obtained
from relevant South African literature for the year 2012
Parameter Distribution Estimate Reference
Change in HIV disease state
Asymptomatic to symptomatic Beta 0.32 [54]
Symptomatic to AIDS Beta 0.20 [55]
AIDS to death Beta 0.21 [54]
Change in drug regimens
First-line to second-line Beta 0.10 [55]
Second-line to third-line Beta 0.01 [56]
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in application for Excel, was used to perform the uncer-
tainty analysis.
The simulation ran a semi-Markov simulation with an-
nual cycles (Fig. 1). Tunnel states could be added to the
semi-Markov model that countered the ‘memoryless’
nature inherent in the models. The vaccine was offered
on a voluntary basis to adolescents from the age of ten
years. The model comprised eight health states. All indi-
viduals were considered HIV negative and healthy at the
start of the model (State 1). The coverage rate deter-
mined who moved into a vaccinated (State 2) or unvac-
cinated (State 3) state. All individuals may transition
into an asymptomatic HIV state (State 4). Individuals
who seroconverted to HIV positive were started on ART
when eligible. Asymptomatic individuals may progress
to a symptomatic (State 5) or AIDS (State 6) state. Every
HIV infected individual may enter the treatment pool
(State 7) which was sub-classified as 1st, 2nd and 3rd
line ART regimens. Every aforementioned health state
may transition to death (State 8). Each cycle carries a
probability of remaining in the current health state or
transitioning to another with the arrows representing
the transition probabilities from one state to another.
Once the vaccine had been stopped, event rates were
assumed to be the same for both arms of the study.
One-way sensitivity analyses evaluated the impact of
single assumptions on cost and outcomes. Probabilistic
sensitivity analysis (PSA) with a bootstrapping technique
of 1000 iterations was used to explore the uncertainty in
the model and evaluate the robustness of the results.
These results were presented as cost-effectiveness scatter
plots and cost-effectiveness acceptability curves. The
PSA data generated was used to determine if the inter-
vention fell below the willingness-to-pay (WTP) thresh-
old. As South Africa does not have a pre-defined WTP
threshold, the Gross Domestic Product (GDP) per capita
(2012) was used as a proxy in accordance with the
WHO Guide to Cost-Effective Analysis [19, 27]. The
WTP threshold was thus defined as US$ 7 508 (ZAR 61
641) per quality adjusted life year (QALY) gained. The
GDP per capita range was adapted from the ‘value of
statistical life’ literature and is theoretically the value of
an additional healthy life year [28]. It is used in the con-
text of this study against LYG (rather than the conven-
tion QALY) as there is no other alternative available to
indicate cost-effectiveness in South Africa.
Cost and cost-effectiveness of a national HIV
vaccination program
The programmatic costs and health implications of a
vaccine implemented at US$ 12 per dose and 60 %
coverage was determined and this was considered the
base case. Using PSA techniques, we were able to esti-
mate the change in cost per capita, the approximate cost
per LYG and finally the cost per death averted at differ-
ent vaccines prices per dose. The change from the base
cost for the program cost was compared with the base-
line vaccine implementation at US$ 12 per dose.
Life table analysis
A multi-state life table approach was used to describe the
differential morbidity and mortality of a population under
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Fig. 1 Model depicting the semi-Markov model of the HIV vaccination strategy. Healthy vaccinated and unvaccinated individuals may enter into
a HIV positive state. They can progress from a HIV infection state to the HIV treatment pool. All states may progress to a death states at a rate
specific to the state they were currently in
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the reference population displaying the HIV associated
mortality experienced by the South African adolescent
population under the comparator model compared with
the outcomes from the adolescent population when ex-
posed to the intervention (which was the vaccine strategy
in addition to the comparator model). Disease related
mortality was referenced from the literature (Table 3). The
study used a cohort life table methodology which calcu-
lated the probability of death of a generation (cohort) over
the course of their lifetime. Cohort life tables use age-
specific mortality rates related to specific cohorts which
allow for known and projected changes in mortality [30].
Within a standard life table, the disease related mortality
was separated from national mortality (as shown in Eq. 1):
Mtot ¼ Mdis þ Mother ð1Þ
Where Mtot is the total mortality identified in the age/
sex group, Mdis is the mortality attributed to the disease
state and Mother is the mortality attributed to all other
causes.
The prevalence estimates for HIV was obtained from
South African National HIV Prevalence, Incidence and
Behaviour Survey, 2012 [2]. The ratio between the com-
parator and the intervention groups was used to calcu-
late the relative reduction in HIV related mortality
attributable to the intervention (reflected in Eq. 2). This
reduction was applied in the life table allowing for
comparisons to be made including the life expectancy,
individuals surviving and the cumulative years lived.
RRm ¼ MiMc ð2Þ
Where RRm is the mortality risk reduction, Mi is the
mortality risk in the intervention group and Mc is the
mortality risk in the comparator group.
Values were entered into a life table to estimate the
impact of the intervention on life expectancy and the
number of life years gained. Generally, a life table esti-
mates the mortality experience of a population and
calculates the life expectancy from birth [31]. The life
expectancy calculated from a life table is represented by
the following formula (Eq. 3) [32]:
ex ¼ TxIx ð3Þ
Where ex is the life expectancy at age X, Tx is the
cumulative person years lived after age X and lx are the
individuals alive at beginning of age X.
The difference in cumulative years lived between the
intervention and comparator groups were used in the in-
cremental cost-effectiveness ratios (ICER) calculations.
The ICER represents the difference in costs between
strategies and the difference in effects (e.g. LYG)
between strategies (Eq. 4). The unit of measurement of
the ICER is US$ per LYG gained.





Where C1 and E1 are the costs and effects of the
standard of care (comparator), and C2 and E2 are the
costs and effects of the intervention.
Years of potential life lost
The years of potential life lost (YPLL) is used to measure
the incidence of ‘premature’ mortality that occurs within
a population to an age at which the death is considered
untimely [33, 34]. The YPLL concept quantifies social
and economic loss as a result of premature death, and
has been useful in assessing specific causes of death tar-
geting younger age groups [35]. The principle of YPLL
incorporates the age at death, and the calculation is able
to mathematically weight the total deaths by applying
values to death at each age (Eq. 5) [34–36].
YPLL ¼ Σ ndix
  70– n  5ð Þ½  ð5Þ
Where nd
i
x is the number of deaths due to HIV/AIDS
from age x to age x + n and n is the width of the age
interval (in this study ten-year age intervals were used)
and 5 represents the number of years till the midpoint
of the age interval is reached.
Cost consequence analysis
The absolute risk reduction (ARR) was then measured
as a percentage. This represented the change in the risk
of an outcome of the intervention in comparison to the
comparator. It was calculated as the difference in the
mean values of the parameter of interest and an example
of the calculation is shown in Eq. 6.
HIV incidencecomparator– HIV incidenceintervention ¼ ARR %½ 
ð6Þ
Where the HIV incidence comparator and HIV incidence
intervention represented mean percentages and the dif-
ference in values was the absolute risk reduction
percentage.
The difference in per capita costs with and without
the intervention was then divided by the ARR values ob-
tained for HIV incidence and HIV mortality to yield the
cost per percentage reduction in disease. The outcomes
for both the ARR and the per percentage reduction in
disease burden was described by gender to highlight the
areas of greatest impact.
Moodley et al. BMC Public Health  (2016) 16:330 Page 6 of 13
Model assumptions
All participants entering the model were considered
sexually naïve. Drop-out rates were not accounted for as
all children of school-going age were assumed to be at-
tending school. The model assumed that the rollout and
uptake of HIV counselling and testing (HCT) strategies
and the national rollout of the HIV vaccination strategy
occurred within the school-based health services that
provided comprehensive care to all socio-economic
levels of learners. Finally, the model assumed good up-
take of school-based health services given the provision
of care in a familiar and safe environment with no en-
croachment on school attendance. As no formal pilot
studies have been reported, there remains no validation
of this assumption.
Ethical consideration
Ethical approval for the study was obtained from the
Human Research Ethics Committee (Medical) of the
University of the Witwatersrand.
Results
Costs of models
The annual per capita cost of the comparator was US$
80. Annual HIV vaccination per capita cost was calcu-
lated at US$ 89, representing an 11 % increase in costs.
Table 4 describes the complete breakdown of these
costs. There is no appreciable difference in human
resources and laboratory costs associated with the
vaccine intervention, though the intervention does
represent a saving on both these costs. However, the
intervention does predict an increase (31 %) in pharma-
ceutical costs driven by the need for vaccine boosters
to attain durable protection. The vaccine price consid-
ered in Table 4 was US$ 12.
Uncertainty analysis
The cost and cost-effectiveness of a national HIV
vaccination program
Implementing a South African national HIV vaccination
program at the base vaccine cost of US$12 per dose
(Table 5) would be considered cost-effective at US$ 5
per LYG. When benchmarking this against the WHO
cost-effectiveness criteria (US$ 7508 per QALY gained),
a HIV vaccine at US$ 12 is deemed highly cost-effective.
However, introduction of the HIV vaccine at consider-
ably reduced price per dose will significantly impact the
future sustainability of the program. At the low vaccine
cost of US$ 6, the program cost will be reduced by 5 %
(US$ 52 million) of the base vaccination program; and
will result in an ICER of US$ 2 per LYG. The very low
vaccine price of US$ 2 would yield even better results –
an ICER of US$ 1 per LYG with a 9 % reduction (US$
84 million) in the program costs compared with the
baseline vaccination strategy.
Impact of coverage on cost and life expectancy
Table 6 explores the impact of initial vaccine and subse-
quent booster coverage on cost and life expectancy. To
vary the coverage annually would be computationally
challenging, hence the combination of the initial vaccine
and the administration of the annual booster was con-
sidered as a continuum i.e. if the initial vaccine coverage
was 40 %, then the booster coverage considered was also
40 %. Increasing the vaccine coverage would result in
significantly increased financial investment. However
increasing coverage also translated to improved life ex-
pectancy. The increased cost has to be weighed against
the improved health outcomes, before the strategy is
deemed cost-effective. There would also have to be con-
sideration of the impact of other vaccine characteristics.
Probabilistic sensitivity analysis
ICER and WTP results
The uncertainty around the ICER was assessed using
probabilistic sensitivity analysis. The HIV vaccine inter-
vention yielded an ICER of US$ 4.98 per LYG (95 % CI
ZAR 2.77–11.61). National projections of the interven-
tion programme were estimated to cost US$ 1017 mil-
lion annually. This represents a US$ 104 million (11 %)
increase on the comparator cost of US$ 913 million.
Aside from the need for boosters driving the cost, it
should be borne in mind that the vaccine is anticipated
to reach approximately 6 million HIV negative 10–19
year old adolescents compared with the comparator
strategy providing ART to 78 126 adolescents of the
same age group. The intervention, however, would trans-
late to a mean cumulative gain of 23.6 million LYG
(95 % CI 8.48–34.3 million years) in the population.
Apart from demonstrating the cost-effectiveness of the
vaccine intervention, Fig. 2 was designed to evaluate the
impact of differing vaccine efficacies on the ICER. At a
vaccine efficacy of 30 %, the iterations lie on either side
of the WTP threshold indicating that the intervention
may not be cost-effective. However, at the vaccine effi-
cacy of 50 % and 70 %, most iterations were considerably
below the GDP per capita of South Africa, 2012. Based
on this GDP, the intervention would be considered
below the WTP threshold defined by the World Health
Organization (WHO) and thus deemed to be highly
cost-effective [19].
Life expectancy and potential years of life lost
The simulation of the life table results are presented in
Table 7. Application of the intervention in the 10–19
year age group resulted in a 2.5 year increase in life ex-
pectancy, as well as a significant increase in cumulative
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gain of years lived in the age group. Importantly, as a
result of the increase in life expectancy noted in the
10–19 year group, there was a reported increase doc-
umented in the subsequent age groups. The PYLL
from HIV/AIDS contributing to ‘premature’ death is
also given in Table 7. It is here that the impact of
(the vaccine is demonstrated as there is a years of life
lost without the vaccine (70 640) is considerably
higher than the years lost with the vaccine interven-
tion (48 400).
Cost consequence results
The 10 year absolute risk reductions in HIV associated
mortality and incidence potentially offered by the HIV
Table 4 Model components and cost comparison of the HIV vaccination program (US$). Complete breakdown of costs relating to
the intervention and the comparator. The intervention comprises both the vaccine strategy and the comparator costs
Cost category Per capita expenditure
Intervention Comparator Difference (% change)
Laboratory 12.73 13.09 0.35 (-2.78)
HIV rapid testing 1.06 1.41
CD4 count 4.05 4.05
Pap smear 1.13 1.13
Viral load 5.95 5.95
Creatinine 0.53 0.53
Pharmaceuticals 39.86 30.21 9.64 (+31.92)
STI treatment 1.11 0.92
Condom distribution 1.35 1.12
Contraception 0.77 0.63
Anti-retroviral therapy 27.34 27.34
Vaccine 8.94 0.00
Vaccine deliverya 0.15 0.00
Bactrim® prophylaxis 0.20 0.20
Human resources 35.94 36.67 0.63 (-1.76)
PHC nurse 20.70 22.24
Counsellor 11.03 11.81
Enrolled nursing assistant 1.68 0.00
Medical officer 0.46 0.46
Medical specialist 2.07 2.07
Transport b 0.47 0.47 - -
Total 89.00 80.34
aVaccine delivery includes the needle, syringe and alcohol swab for administration
bCalculated from average car rental cost incurred in providing a school-based service
Table 5 Cost –effectiveness of a national HIV vaccination program at varied vaccine prices, 2012. The programmatic cost
implications of varying the vaccine cost per dose were examined. The cost values reflect annual expenditure. At baseline (shaded), a
vaccine at the cost of US$ 12 per dose would result in an annual cost of approximately US$ 1017 million. This represents a US$ 9
increase from the base cost per capita (Table 4). All other values have been calculated relative to the base vaccination strategy
Vaccine pricing Program cost (millions) Cost per
Structure Per dose Total Change from base (%) Capitaa LYG Death averted
Very low 2 933 -84 (-9) 1 1 421
Low 6 967 -50 (-5) 4 2 1106
Base cost 12 1017 - - 9 4 2131
Medium 18 1067 50 (+5) 13 6 3161
High 24 1118 101 (+10) 18 8 4189
a increase in cost per capita
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vaccine intervention was projected using data modelled.
Table 8 described a detailed breakdown of costs to high-
light the differences in vaccine impact between the gen-
ders. While all scenarios reflected an improvement in
HIV related health outcome, the reduction in HIV inci-
dence among females was notable (0.53 %), particularly
given their high burden of disease.
Discussion
The study aimed to assess the cost-effectiveness of na-
tional rollout of the hypothetical HIV vaccine to school-
based adolescents. The South African HIV epidemic is
widely acknowledged to be generalized, with adolescents
and young adults disproportionately at risk for HIV [37].
In 2013, South Africa reported 16 % of the global HIV
incidence despite concerted efforts at the national level
ranging from increasing ART distribution by 75 % be-
tween 2009 and 2011 to boasting the largest and most
established condom distribution program in the world
[2, 38]. This earmarked adolescents as a key population
to be reached if HIV prevention strategies are to impact
incidence and if HIV mortality rates are to be signifi-
cantly curtailed [37]. While the introduction of a poten-
tial HIV vaccine in schools represents a significant
financial investment, the health outcomes in terms of
improved life expectancy, markedly decreased potential
years of life lost and decreases in HIV mortality and
incidence are substantive. Life expectancy was equally
influenced by vaccine coverage rates, while the assess-
ment of cost-effectiveness was found to be sensitive to
the vaccine efficacy.
The life table findings together with the conventionally
accepted thresholds for cost-effectiveness being met
demonstrate the financial plausibility of HIV vaccine im-
plementation [19]. Importantly, the vaccine remained
cost-effective even at higher prices per dose examined
but at substantially greater programmatic costs. Annual
HIV vaccination represents a substantial increase in
costs per capita at base coverage of 60 % of HIV negative
adolescents. This constitutes a significant investment
considering the intense competition of several compet-
ing burdens of disease on a constrained South African
health budget [39]. As much as the long term financial
sustainability of the burgeoning ART program has been
brought into question, the implementation of a HIV vac-
cine program over several decades may prove equally
daunting. It is important to bear in mind that the
comparator cost reflects those currently on treatment (ex-
cluding the treatment shortfall of approximately 58 % [1])
and thus represents a gross underestimation of what we
should be paying if those unable to access treatment were
indeed able to access it. Another major consideration is
Table 6 One-way sensitivity analysis of coverage on health
outcomes. By varying the coverage rates, we are able to
demonstrate how an increased number of doses drive the
intervention costs up
Cost (million US$)
Coverage Comparator Intervention Increase in cost Life expectancy
40 % 913 982 70 54.6 years
60 % 913 1017 104 55.5 years






















Years of life saved (x 1000) (incremental effect)
WTP = US$ 7 508 (ZAR 61 641) 
per life year gained using 2012 
average dollar value.
Fig. 2 Willingness-to-pay analysis explored by varying vaccine efficacy. This figure shows the scatter plot of the costs and health outcomes from
the probabilistic sensitivity analysis. The incremental cost is the difference in costs between the current treatment program and the vaccine
program. Similarly, the incremental effect reflects the difference in health outcomes between the vaccine program and the current treatment
program. The health outcomes are measured in years of life saved
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that the upscaling of ART may not impact the HIV inci-
dence as definitively as a primary preventative strategy
may. It must be remembered that while averting infections
has a cost attached from a government perspective, it may
also give rise to the substantial financial gains of reducing
the demand for ART [40].
South Africa has successfully negotiated reduced
pricing for ART and HPV vaccines in the past, and
this bodes well for future procurement of HIV vac-
cines [23, 24], as the price is undetermined at this
point. If vaccine development fails to reduce the number
of annual boosters required to maintain protection, then
the pricing represents a key factor in deciding the cost-
effectiveness of the intervention. Apart from the eco-
nomic impact, HIV vaccine implementation has the
capacity to influence long term health outcomes. The
mean cumulative gain of LYG could support efforts to
improve life expectancy in the country, an area
identified as a strategic output of the National Service
Delivery Agreement [5].
The South African epidemic is predominantly hetero-
sexual. This work represents an over-simplification of
the rather complex sexual networking structures at play
in the South African HIV epidemic. Nonetheless, those
individuals at high risk may still acquire infection as-
cribed to repeated risk exposures despite the protection
conferred by the vaccine compared with those at low
risk. At a population level, the premise remains that a
partially effective vaccine may still avert or delay infec-
tion even if it is unable to completely prevent an infec-
tion from establishing [41]. Assessment of a partially
effective vaccine in the United States of America (USA)
emphasizes that even modest and temporal reductions
in HIV infections have important benefits at the popula-
tion level [42]. Andersson et al demonstrated similar
health benefits to the USA study when modelling the
RV144/Thai trial vaccine in South Africa, but cautioned
that a vaccine of limited duration could only be effective
with high coverage levels, which translated to millions of
doses [43].
Adolescents are a critical target for this intervention.
Apart from being a key population identified in the trans-
mission of HIV, adolescents in a school environment appear
more easily accessible as a target group considering that
more commonly identified high risk groups such as com-
mercial sex workers are often harder to reach due to stigma
and marginalization [43]. However, adolescents have histor-
ically encountered barriers in trying to access health services
in South Africa from confidentiality issues to the judgmen-
tal attitudes of staff. It is not surprising that they often do
not return for follow up care [9]. The school environment
could be deemed a “safe space” for peer discussion
and accessibility of relevant health services. Neglect-
ing the comprehensive health needs and barriers to
Table 7 Life table analysis and YPLL for 10-19 year age group
Age (x) No vaccination (comparator) Vaccination (intervention)
Life expectancy Ix Tx ex Ix Tx ex
(millions) (millions) (millions) (millions)
10–19 10.0 529.1 53.0 10.0 553.6 55.5
20–29 9.8 429.9 43.7 9.9 454.4 46.1
30–39 9.3 334.4 36.1 9.4 358.2 38.2
40–49 8.3 246.8 29.9 8.6 268.3 31.2
50–59 7.1 170.0 23.9 7.6 187.2 24.6
60+ 5.8 105.5 18.2 6.3 117.4 18.6
YPLL
10–19 70 640 48 400
The movement of the vaccinated population aged 10 – 19 years of age is tracked through the life table. Columns Ix describes the impact of the intervention in
terms of mortality reduction, columns Tx reflects the combined years lived with and without the intervention and columns ex reflect the increase in life
expectancy attributable to the intervention
Ix – individuals surviving, Tx – cumulative years lived, ex – remaining life expectancy at age x
Table 8 Disease risk reduction and cost consequences. The
absolute risk reduction was estimated over a 10 year period
10 year risk: mean % (SE) Absolute risk Cost
Intervention Comparator reduction consequencea
Total
Incidence 1.08 (0.08) 1.49 (0.15) 0.42 % 20.87
Mortality 1.05 (0.01) 1.45 (0.04) 0.41 % 21.36
Male
Incidence 1.09 (0.09) 1.51 (0.15) 0.42 % 20.67
Mortality 1.10 (0.02) 1.52 (0.05) 0.42 % 20.45
Female
Incidence 1.40 (0.12) 1.94 (0.22) 0.53 % 16.29
Mortality 1.03 (0.02) 1.42 (0.04) 0.39 % 22.05
HIV human immunodeficiency virus; SE standard error
aper 1 % reduction in risk
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care of this adolescent population has the potential to
undermine the success of HIV prevention initiatives
[44]. Further, low social acceptability of HIV vaccines
fueled by the fear of vaccines and poor side effect
profiles present potential deterrents to uptake and
coverage [45]. It is understandably difficult for hypo-
thetical scenarios to emulate real-life behavioral
changes but knowledge of these factors underscores
the need for comprehensive sexual education and risk
reduction counselling; which could prove more plaus-
ible in the school environment [46].
This study had several limitations. Firstly, it is unclear
to what degree behavioral disinhibition may occur fol-
lowing vaccination as this was not assessed in the model.
Changes in sexual risk behavior post HIV vaccination
are poorly understood in the African setting [46]. In high
HIV prevalence communities like South Africa, a de-
crease in condom use even with stable partners would
likely result in an increase in HIV rates [46]. In fact,
South African data has inferred that poor comprehen-
sion of the ‘low-efficacy’ concept was associated with a
reported potential decrease in condom use. It is further
postulated that the degree of behavioral disinhibition
may depend largely on the manner in which the vaccine
effects are marketed to the public and vaccine recipients
alike [40]. The impact of risk compensation becomes
critical when considering the low efficacy displayed by
the candidate vaccines thus far [46]. Secondly, the study
was unable to assess the effects of herd immunity. Not-
ably, Long et al. alluded to partial efficacy vaccines pro-
viding some benefits to the unvaccinated population
through herd immunity [42]. This is particularly import-
ant considering the low coverage rates of childhood
vaccinations in South Africa as it speaks directly to the
country’s capacity to introduce and implement a HIV
vaccine [22]. At 60 % coverage, this program calls for an
unprecedented 5.9 million adolescents to be vaccinated.
Given this, it is not surprising that implementation costs
are high. Thirdly, the provider perspective was consid-
ered as the largest burden of direct medical program
costs will be borne by the healthcare sector. Although
the societal costs were not analyzed, its contribution
would be substantial and could improve the overall cost-
effectiveness of the vaccine. Fourthly, booster vaccina-
tions were not assessed in the original RV144/Thai trial
work [42]. Therefore the assumption that booster vac-
cination would provide the same protective effects as
the initial vaccination was hypothetical. There has been
limited description of this in the literature [46]. Add-
itionally, administration costs would drastically increase
the program costs with the need for annual boosters.
This is the key cost factor implicated in the difference
between the comparator and intervention cost. However,
it is hoped that attrition rates of vaccine recipients
would be minimized by targeting the relatively stable
school population. Lastly, this study has considered HIV
vaccination as an isolated intervention apart from
the ART rollout and condom distribution. In the
clinical setting, this intervention would probably
work synergistically with other prevention strategies
such as male medical circumcision and an optimal
combination of strategies should be better defined
once data becomes available [40, 42]. As discussed
earlier, the limited success achieved in curbing the
national HIV incidence by the current public sector
HIV prevention strategies warrants the evaluation of
strategies on its individual merits.
Conclusion
In conclusion, these findings suggests that a national
HIV vaccine program administered to adolescents in
South Africa would be a cost-effective means for redu-
cing the massive disease and economic burden of HIV.
The implications on health outcomes are significant with
reductions in HIV associated mortality and incidence
and improved life expectancy demonstrated by the
model. However, a vaccine with more durable protection
and requiring fewer boosters would considerably reduce
costs. While this work provides decision makers with
objective baseline data for considering the adoption of
the potential HIV vaccination intervention nationally,
more realistic estimates on cost and disease burden
should be gauged once the efficacy, duration of protec-
tion and vaccine cost is determined.
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